Collaborators GBDO, Afshin A, Forouzanfar MH, Reitsma MB, Sur P, Estep K, et al. Health Effects of Overweight and Obesity in 195 Countries over 25 Years. N Engl J Med. 2017;377(1):13–27. https://doi.org/10.1056/NEJMoa1614362.

Article  Google Scholar 

Collaboration NCDRF. Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet. 2024;403(10431):1027–50. https://doi.org/10.1016/S0140-6736(23)02750-2.

Article  Google Scholar 

Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation. 2014;129(25 Suppl 2):S102. https://doi.org/10.1161/01.cir.0000437739.71477.ee.

Article  PubMed  Google Scholar 

Rosenstock J, Wysham C, Frias JP, Kaneko S, Lee CJ, Fernandez Lando L, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143–55. https://doi.org/10.1016/S0140-6736(21)01324-6.

Article  CAS  PubMed  Google Scholar 

Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023;402(10402):613–26. https://doi.org/10.1016/S0140-6736(23)01200-X.

Article  CAS  PubMed  Google Scholar 

Urva S, Coskun T, Loh MT, Du Y, Thomas MK, Gurbuz S, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400(10366):1869–81. https://doi.org/10.1016/S0140-6736(22)02033-5.

Article  CAS  PubMed  Google Scholar 

Jastreboff AM, Kaplan LM, Frias JP, Wu Q, Du Y, Gurbuz S, et al. Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial. N Engl J Med. 2023;389(6):514–26. https://doi.org/10.1056/NEJMoa2301972.

Article  CAS  PubMed  Google Scholar 

Saxena AR, Frias JP, Brown LS, Gorman DN, Vasas S, Tsamandouras N, et al. Efficacy and safety of oral small molecule glucagon-like peptide 1 receptor agonist danuglipron for glycemic control among patients with type 2 diabetes: a randomized clinical trial. JAMA Netw Open. 2023;6(5):e2314493. https://doi.org/10.1001/jamanetworkopen.2023.14493.

Article  PubMed  PubMed Central  Google Scholar 

Wharton S, Blevins T, Connery L, Rosenstock J, Raha S, Liu R, et al. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N Engl J Med. 2023;389(10):877–88. https://doi.org/10.1056/NEJMoa2302392.

Article  CAS  PubMed  Google Scholar 

Zheng Z, Zong Y, Ma Y, Tian Y, Pang Y, Zhang C, et al. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct Target Ther. 2024;9(1):234. https://doi.org/10.1038/s41392-024-01931-z.

Article  PubMed  PubMed Central  Google Scholar 

Drucker DJ. The expanding landscape of GLP-1 medicines. Nat Med. 2026. https://doi.org/10.1038/s41591-025-04124-5.

Article  PubMed  Google Scholar 

He L, Wang J, Ping F, Yang N, Huang J, Li Y, et al. Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials. JAMA Intern Med. 2022;182(5):513–9. https://doi.org/10.1001/jamainternmed.2022.0338.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li Z, Han Z, Sun R, Xuan X, Huang C. Long-term efficacy trajectories of GLP-1 receptor agonists: a systematic review and network meta-analysis. Diabetes Metab Syndr Obes. 2025;18:3611–24. https://doi.org/10.2147/DMSO.S539822.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Piuri G, Zocchi M, Della Porta M, Ficara V, Manoni M, Zuccotti GV, et al. Magnesium in Obesity, Metabolic Syndrome, and Type 2 Diabetes. Nutrients. 2021. https://doi.org/10.3390/nu13020320.

Article  PubMed  PubMed Central  Google Scholar 

Alshwaiyat NM, Ahmad A, Wan Hassan WMR, Al-Jamal HAN. Association between obesity and iron deficiency (Review). Exp Ther Med. 2021;22(5):1268. https://doi.org/10.3892/etm.2021.10703.

Article  CAS  PubMed  PubMed Central  Google Scholar 

McKay J, Ho S, Jane M, Pal S. Overweight & obese Australian adults and micronutrient deficiency. BMC Nutr. 2020;6:12. https://doi.org/10.1186/s40795-020-00336-9.

Article  PubMed  PubMed Central  Google Scholar 

Cepeda-Lopez AC, Aeberli I, Zimmermann MB. Does obesity increase risk for iron deficiency? A review of the literature and the potential mechanisms. Int J Vitam Nutr Res. 2010;80(4–5):263–70. https://doi.org/10.1024/0300-9831/a000033.

Article  CAS  PubMed  Google Scholar 

Tan Q, Akindehin SE, Orsso CE, Waldner RC, DiMarchi RD, Muller TD, et al. Recent advances in incretin-based pharmacotherapies for the treatment of obesity and diabetes. Front Endocrinol (Lausanne). 2022;13:838410. https://doi.org/10.3389/fendo.2022.838410.

Article  PubMed  PubMed Central  Google Scholar 

Graaf C, Donnelly D, Wootten D, Lau J, Sexton PM, Miller LJ, et al. Glucagon-like peptide-1 and its class B G protein-coupled receptors: a long march to therapeutic successes. Pharmacol Rev. 2016;68(4):954–1013. https://doi.org/10.1124/pr.115.011395.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hui H, Farilla L, Merkel P, Perfetti R. The short half-life of glucagon-like peptide-1 in plasma does not reflect its long-lasting beneficial effects. Eur J Endocrinol. 2002;146(6):863–9. https://doi.org/10.1530/eje.0.1460863.

Article  CAS  PubMed  Google Scholar 

Meier JJ, Nauck MA, Kranz D, Holst JJ, Deacon CF, Gaeckler D, et al. Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes. 2004;53(3):654–62. https://doi.org/10.2337/diabetes.53.3.654.

Article  CAS  PubMed  Google Scholar 

Furman BL. The development of Byetta (exenatide) from the venom of the Gila monster as an anti-diabetic agent. Toxicon. 2012;59(4):464–71. https://doi.org/10.1016/j.toxicon.2010.12.016.

Article  CAS  PubMed  Google Scholar 

Frias JP, Davies MJ, Rosenstock J, Perez Manghi FC, Fernandez Lando L, Bergman BK, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503–15. https://doi.org/10.1056/NEJMoa2107519.

Article  CAS  PubMed  Google Scholar 

Aronne LJ, Horn DB, le Roux CW, Ho W, Falcon BL, Gomez Valderas E, et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med. 2025;393(1):26–36. https://doi.org/10.1056/NEJMoa2416394.

Article  CAS  PubMed  Google Scholar 

Tamborlane WV, Barrientos-Perez M, Fainberg U, Frimer-Larsen H, Hafez M, Hale PM, et al. Liraglutide in children and adolescents with type 2 diabetes. N Engl J Med. 2019;381(7):637–46. https://doi.org/10.1056/NEJMoa1903822.

Article  CAS  PubMed  Google Scholar 

Wilding JP, Overgaard RV, Jacobsen LV, Jensen CB, le Roux CW. Exposure-response analyses of liraglutide 3.0 mg for weight management. Diabetes Obes Metab. 2016;18(5):491–9. https://doi.org/10.1111/dom.12639.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11–22. https://doi.org/10.1056/NEJMoa1411892.

Article  CAS  PubMed